Dr. Eric Rowinsky earned his MD from Vanderbilt University before completing a residency in Internal Medicine at University of California San Diego and a Fellowship in Medical Oncology at Johns Hopkins University. With a background in clinical-stage biopharmaceutical and biotherapeutic companies, he has served as Chief Medical Officer, Chief Scientific Officer, and Head of Research Development for Clearpath Development and Stemline Therapeutics, focusing on advancing therapeutic assets to predefined human proof-of-concept milestones and developing therapies for cancer stem cells and rare diseases.

Dr. Rowinsky's extensive experience includes roles as President and Executive Chairman of Inspirna, Chief Medical Officer of Hummingbird Biotherapeutics, and Executive Vice President of ImClone Systems. He has held public company directorships at BIND Therapeutics, Biophytis, and Navidea Biopharmaceuticals. Currently, he sits on the boards of Biogen, Fortress Biotech, Purple Biotech, and Verastem. Throughout his career, Dr. Rowinsky has led teams that registered over twelve novel therapies for patients with advanced cancers, making his clinical development experience in oncology invaluable to Radyus clients.